

22/08/2007,10561227.trn

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTASXY1626

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *
SESSION RESUMED IN FILE 'HCAPLUS' AT 13:38:55 ON 10 MAY 2007
FILE 'HCAPLUS' ENTERED AT 13:38:55 ON 10 MAY 2007
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	273.97	627.15
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-39.78	-40.56

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	273.97	627.15
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-39.78	-40.56

FILE 'REGISTRY' ENTERED AT 13:39:03 ON 10 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 9 MAY 2007 HIGHEST RN 934521-72-9
DICTIONARY FILE UPDATES: 9 MAY 2007 HIGHEST RN 934521-72-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:



<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10561227.str

Young, Shawquia, Page 1

22/08/2007,10561227.trn



chain nodes :

7 8 9 10 11 13 18 19 20 21

ring nodes :

1 2 3 4 5 6 12 14 15 16 17 22 23 24 25 26 27

chain bonds :

3-7 6-9 7-8 9-10 9-11 11-12 11-13 17-18 18-19 18-20 19-21 19-22

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 12-14 12-17 14-15 15-16 16-17 22-23 22-27
23-24 24-25 25-26 26-27

exact/norm bonds :

6-9 9-11 11-12 11-13 12-14 12-17 14-15 15-16 16-17 18-19 18-20 19-22

exact bonds :

3-7 7-8 9-10 17-18 19-21

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 22-23 22-27 23-24 24-25 25-26 26-27

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:Atom 13:CLASS 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS
19:CLASS 20:CLASS 21:CLASS 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom

L14 STRUCTURE UPLOADED

=> d l14

L14 HAS NO ANSWERS

L14 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l14

SAMPLE SEARCH INITIATED 13:39:21 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 6 TO ITERATE

22/08/2007,10561227.trn

100.0% PROCESSED 6 ITERATIONS 3 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
PROJECTED ITERATIONS: 6 TO 266
PROJECTED ANSWERS: 3 TO 163

L15 3 SEA SSS SAM L14

=> s l14 full
FULL SEARCH INITIATED 13:39:25 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 82 TO ITERATE

100.0% PROCESSED 82 ITERATIONS 59 ANSWERS
SEARCH TIME: 00.00.01

L16 59 SEA SSS FUL L14

=> file hcaplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	172.10	799.25
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-40.56

FILE 'HCAPLUS' ENTERED AT 13:39:31 ON 10 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907 - 10 May 2007 VOL ISS ISS
FILE LAST UPDATED: 9 May 2007 (20070509/ED)
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN. Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 10 May 2007 VOL 146 ISS 20
FILE LAST UPDATED: 1 May 2007 (20070501/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.


This file contains CAS Registry Numbers for easy and accurate

=> s l16
L17 3 L16

=> d ed abs ibib hitstr 1-3

22/08/2007,10561227.trn

L17 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 07 Oct 2005
Q1




AB The invention relates to title compds., e.g. (I), which are inhibitors of coagulation factors Xa and VIIa and can be used for the prophylaxis and/or treatment of thromboembolic diseases and for the treatment of tumors (no data). Thus, (II) was prepared by condensation of (2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxylic acid 1-tert-Bu ester with 4'-amino-N,N-dimethyl-[1,1'-biphenyl]-2-methanamine, followed by condensation with 4-nitrophenyl chloroformate and 4-chloroaniline, to give

II (no yield). Sixteen title compds. are claimed, and formulations for administration (e.g., injections, suppositories, etc.) are given.
ACCESSION NUMBER: 2005:1075769 HCAPLUS
DOCUMENT NUMBER: 143:347450
TITLE: Synthesis of prolinyl derivatives for use in the treatment of thromboembolic diseases or tumors
INVENTOR(S): Mederski, Werner; Tsaklakidis, Christos; Dorsch, Dieter; Cezanne, Bertram; Gleitz, Johannes
PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany
SOURCE: PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

L17 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 865853-91-4 HCAPLUS
CN 1,2-Pyrrolidinedicarboxamide,
N2-[4-[(2-[(dimethylamino)methyl]-1H-imidazol-1-yl]phenyl)-N1-(4-ethynylphenyl)-4-hydroxy-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 865853-93-6 HCAPLUS
CN 1,2-Pyrrolidinedicarboxamide,
N2-[4-[(2-[(dimethylamino)methyl]-1H-imidazol-1-yl]phenyl)-N1-(4-ethynylphenyl)-4-hydroxy-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L17 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

WO 2005092849	A1 20051006	WO 2005-EP2306	20050304
M: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,			
ZN			
RM: BW, GH, GM, GR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
DE 102004014945	A1 20051013	DE 2004-102004014945	20040326
AU 2005225489	A1 20051006	AU 2005-225489	20050304
CA 2561057	A1 20051006	CA 2005-2561057	20050304
EP 1735279	A1 20061227	EP 2005-715737	20050304
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, LV			
CN 1938269	A 20070328	CN 2005-8009735	20050304
PRIORITY APPLN. INFO.:		DE 2004-102004014945A	20040326
		WO 2005-EP2306	W 20050304

OTHER SOURCE(S): MARPAT 143:347450
IT 865853-89-0P 865853-91-4P 865853-93-6P
865853-95-8P 865853-97-0P 865853-99-2P
865854-02-0P 865854-03-1P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of proline derivs. for treatment of thromboembolic diseases or tumors)
RN 865853-89-0 HCAPLUS
CN 1,2-Pyrrolidinedicarboxamide, N2-[2'-[(dimethylamino)methyl][1,1'-biphenyl]-4-yl]-N1-(4-ethynylphenyl)-4-hydroxy-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 865853-95-8 HCAPLUS
CN 1,2-Pyrrolidinedicarboxamide,
N2-[4-[(2-[(dimethylamino)methyl]-1H-imidazol-1-yl]phenyl)-N1-(4-ethynylphenyl)-4-hydroxy-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 865853-97-0 HCAPLUS
CN 1,2-Pyrrolidinedicarboxamide,
N2-[4-[(2-[(dimethylamino)methyl]-1H-imidazol-1-yl]phenyl)-N1-(4-ethynylphenyl)-4-hydroxy-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 865853-99-2 HCAPLUS
CN 1,2-Pyrrolidinedicarboxamide, N2-[4-[(dimethylamino)iminomethyl]-2-

22/08/2007,10561227.trn


L17 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
fluorophenyl]-N1-(4-ethynylphenyl)-4-hydroxy-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 865854-02-0 HCAPLUS
CN 1,2-Pyrrolidinedicarboxamide, N2-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]-N1-(4-ethynylphenyl)-4-hydroxy-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 865854-03-1 HCAPLUS
CN 1,2-Pyrrolidinedicarboxamide, N2-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]-N1-(4-ethynylphenyl)-4-hydroxy-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L17 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN
RD Entered STN: 30 Jun 2005
GI



AB Title compds., e.g. (I), are claimed as inhibitors of coagulation factor Xa and are claimed for use for the prophylaxis and/or therapy of thromboembolic diseases and in the treatment of tumors, as well as kits containing the compds. of interest. Thus, the title compds. were prepared,


e.g., by condensation of (2R,4R)-1-(4-chlorophenylcarbamoyl)-4-hydroxyproline and N-(4-aminophenyl)-2-dimethylamino-N-methylacetamide in DMF using N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride as condensing agent. In pharmacol. testing, I had receptor affinity IC50 values of 17.0 nM and 25.0 M using FXa and TP/FVIIa receptors, resp. (no details given). Various formulations for administering the title compds. therapeutically are given.

ACCESSION NUMBER: 2005:564637 HCAPLUS
DOCUMENT NUMBER: 143:97636
TITLE: Synthesis of prolinylarylacetamides as coagulation factor Xa inhibitors for use in the prevention or treatment of thromboembolic diseases or tumors
Maderaki, Werner; Tsaklakidis, Christos; Dorsch, Dieter; Cozanne, Bertram; Gleitz, Johannes
PATENT ASSIGNER(S): Merck Patent G.m.b.H., Germany
SOURCE: PCT Int. Appl., 65 pp.
CODEN: PIXX2D
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005058817	A1	20050630	WO 2004-EP13509	20041126
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CP, CO, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
DR 10358814	A1	20050721	DE 2003-10358814	20031216
AU 2004299197	A1	20050630	AU 2004-299197	20041126

Young, Shawquia, Page 5

L17 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L17 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CA 2549589 A1 20050630 CA 2004-2549589 20041126
EP 1697318 A1 20060906 EP 2004-820404 20041126
R: AT, BR, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS
CN 1894210 A 20070110 CN 2004-80037698 20041126
BR 2004017630 A 20070327 BR 2004-17630 20041126
PRIORITY APPLN. INFO.: DE 2003-10358814 A 20031216
WO 2004-EP13509 W 20041126

OTHER SOURCE(S): MARPAT 143:97636
IT 855855-42-4 855855-48-0
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
inhibitors (preparation of prolinylarylacetamides as coagulation factor Xa inhibitors for prevention or treatment of thromboembolic diseases or tumors)

RN 855855-42-4 HCAPLUS
CN 1,2-Pyrrolidinedicarboxamide, N2-[4-[(dimethylamino)acetyl]methylamino]phenyl]-N1-(4-ethynylphenyl)-4-hydroxy-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 855855-48-0 HCAPLUS
CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-4-hydroxy-N2-[4-[(methoxyacetyl)methylamino]phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L17 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L17 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 23 Dec 2004
Q1

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R = H, X, A, etc.; R1 = H, =O, halo, etc.; R2 = H, halo, A, R3 = (un)substituted aromatic heterocycle containing 1-4 N, O, S atoms; X = aryl, arylalkyl, het, etc.; A = (un)substituted cycloalkyl] and their pharmaceutically acceptable salts and formulations were prepared For example, condensation of proline II, e.g., prepared from BOC-methoxyproline in 3-steps, and 4-nitrophenylchloroformate and 4-ethynylaniline afforded claimed pyrrolidinyldicarboxylic III in 40% yield. In coagulation factor Xa receptor affinity binding assays, 14-examples of compds. I exhibited IC50 values ranging from 1.1-4.8 nM, i.e., the IC50 value of pyrrolidinyldicarboxylic III was 1.3 nM. Compds. I are claimed to be useful as factor Xa and factor VIIa inhibitors for the treatment of thromboembolic diseases.

ACCESSION NUMBER: 2004:1124627 HCAPLUS
DOCUMENT NUMBER: 142:74838
TITLE: Preparation of pyrrolidine-1,2-dicarboxylic acids and related compounds as coagulation factor Xa and factor VIIa inhibitors
INVENTOR(S): Mederski, Werner; Tsaklakidis, Christos; Dorsch, Dieter; Cezanne, Bertram; Gleitz, Johannes
PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany
SOURCE: PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004110433	A1	20041223	WO 2004-EP5717	20040527
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HK, ID, IL, IN, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RN:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SH, TD, TG			
DE 10327428	A1	20050105	DE 2003-10327428	20030618
DE 10329457	A1	20050120	DE 2003-10329457	20030701
AU 2004246766	A1	20041223	AU 2004-246766	20040527
CA 2529453	A1	20041223	CA 2004-2529453	20040527

L17 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
EP 1633346 A1 20060315 EP 2004-735007 20040527
EP 1633346 B1 20060823
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
BR 2004011466 A 20060711 BR 2004-11466 20040527
CN 1809346 A 20060728 CN 2004-80016955 20040527
AT 337000 T 20060915 AT 2004-735007 20040527
JP 2006527708 T 20061207 JP 2006-515798 20040527
US 2007093472 A1 20070426 US 2005-561227 20051219
PRIORITY APPLN. INFO.: DE 2003-10327428 A 20030618
DE 2003-10329457 A 20030701
WO 2004-EP5717 W 20040527

OTHER SOURCE(S): MARPAT 142:74838
IT 814263-98-4P 814263-99-5P 814264-00-1P
814264-01-2P 814264-02-3P 814264-03-4P
814264-04-5P 814264-05-6P 814264-06-7P
814264-07-8P 814264-08-9P 814264-09-0P
814264-10-3P 814264-11-4P 814264-12-5P
814264-13-6P 814264-14-7P 814264-15-8P
814264-16-9P 814264-17-0P 814264-18-1P
814264-19-2P 814264-20-5P 814264-21-6P
814264-22-7P 814264-23-8P 814264-24-9P
814264-25-0P 814264-26-1P 814264-27-2P
814264-28-3P 814264-29-4P 814264-30-7P
814264-31-8P 814264-32-9P 814264-33-0P
814264-34-1P 814264-35-2P 814264-36-3P
814264-37-4P 814264-38-5P 814264-39-6P
814264-40-9P 814264-41-0P 814264-42-1P
814264-43-2P 814264-44-3P 814264-45-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrrolidinyldicarboxylic acids and related compds. as factor Xa and factor VIIa inhibitors)


RN 814263-98-4 HCAPLUS
CN 1,2-Pyrrolidinedicarboxamide,
N1-(4-ethynylphenyl)-4-methoxy-N2-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L17 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 814263-99-5 HCAPLUS
CN 1,2-Pyrrolidinedicarboxamide,
N1-(4-ethynylphenyl)-4-methoxy-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 814264-00-1 HCAPLUS
CN 1,2-Pyrrolidinedicarboxamide,
N1-(4-ethynylphenyl)-4-methoxy-N2-[3-methyl-4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 814264-01-2 HCAPLUS
CN 1,2-Pyrrolidinedicarboxamide,
N1-(4-ethynylphenyl)-4-hydroxy-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


22/08/2007,10561227.trn

L17 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 814264-02-3 HCAPLUS
CN 1,2-Pyrrolidinedicarboxamide,
4-ethoxy-N1-(4-ethynylphenyl)-N2-[3-methyl-4-
(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 814264-03-4 HCAPLUS
CN 1,2-Pyrrolidinedicarboxamide,
N1-(4-ethynylphenyl)-N2-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L17 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 1,2-Pyrrolidinedicarboxamide,
N1-(4-ethynylphenyl)-N2-[3-methyl-4-(3-oxo-4-morpholinyl)phenyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 814264-07-8 HCAPLUS
CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-N2-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 814264-08-9 HCAPLUS
CN 1,2-Pyrrolidinedicarboxamide,
N1-(4-ethynylphenyl)-N2-[2-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-4-methoxy-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 814264-09-0 HCAPLUS
CN 1,2-Pyrrolidinedicarboxamide, 4-ethoxy-N1-(4-ethynylphenyl)-N2-[4-(2-oxo-


Young, Shawquia, Page 7

L17 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 814264-04-5 HCAPLUS
CN 1,2-Pyrrolidinedicarboxamide,
N1-(4-ethynylphenyl)-4-hydroxy-N2-[3-methyl-4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 814264-05-6 HCAPLUS
CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 814264-06-7 HCAPLUS


L17 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
1(2H)-pyridinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 814264-10-3 HCAPLUS
CN 1,2-Pyrrolidinedicarboxamide,
N1-(4-ethynylphenyl)-N2-[2-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 814264-11-4 HCAPLUS
CN 1,2-Pyrrolidinedicarboxamide,
4-ethoxy-N1-(4-ethynylphenyl)-N2-[2-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 814264-12-5 HCAPLUS

22/08/2007,10561227.trn


L17 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 1,2-Pyrrolidinedicarboxamide,
N1-(4-ethynylphenyl)-N2-[2-fluoro-4-(3-oxo-4-
morpholinyl)phenyl]-4-hydroxy-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 814264-13-6 HCAPLUS
CN 1,2-Pyrrolidinedicarboxamide, 4-ethoxy-N1-(4-ethynylphenyl)-N2-[4-(2-oxo-1-(2H)-pyrazinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 814264-14-7 HCAPLUS
CN 1,2-Pyrrolidinedicarboxamide,
4-ethoxy-N1-(4-ethynylphenyl)-N2-[4-(2-oxo-1-
piperidinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L17 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 814264-17-0 HCAPLUS
CN 1,2-Pyrrolidinedicarboxamide,
4-ethoxy-N1-(4-ethynylphenyl)-N2-[4-(3-oxo-4-
morpholinyl)phenyl]-, (2S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 814264-18-1 HCAPLUS
CN 1,2-Pyrrolidinedicarboxamide, 4-ethoxy-N1-(4-ethynylphenyl)-N2-[4-(2-oxo-1-(2H)-pyrazinyl)phenyl]-, (2S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 814264-19-2 HCAPLUS
CN 1,2-Pyrrolidinedicarboxamide,
N1-(4-ethynylphenyl)-4-hydroxy-N2-[4-(2-oxo-1-
piperidinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L17 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 814264-15-8 HCAPLUS
CN 1,2-Pyrrolidinedicarboxamide,
4-ethoxy-N1-(4-ethynylphenyl)-N2-[3-fluoro-4-
(2-oxo-1(2H)-pyridinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 814264-16-9 HCAPLUS
CN 1,2-Pyrrolidinedicarboxamide,
4-ethoxy-N1-(4-ethynylphenyl)-N2-[4-(3-oxo-4-
morpholinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L17 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




Absolute stereochemistry.



RN 814264-21-6 HCAPLUS
CN 1,2-Pyrrolidinedicarboxamide,
N1-(4-ethynylphenyl)-4-hydroxy-N2-[3-methyl-
4-(2-oxo-1-piperidinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 814264-22-7 HCAPLUS
CN 1,2-Pyrrolidinedicarboxamide,
N1-(4-ethynylphenyl)-4-hydroxy-N2-[3-methyl-
4-(2-oxo-1-piperidinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

22/08/2007,10561227.trn


L17 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
4-(2-oxo-1-pyrrolidinyl)phenyl)-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 814264-23-8 HCAPLUS
CN 1,2-Pyrrolidinedicarboxamide,
4-ethoxy-N1-(4-ethynylphenyl)-N2-[3-fluoro-4-
(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 814264-24-9 HCAPLUS
CN 1,2-Pyrrolidinedicarboxamide,
4-ethoxy-N1-(4-ethynylphenyl)-N2-[3-fluoro-4-
(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L17 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
4-(2-oxo-1(2H)-pyridinyl)phenyl)-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 814264-28-3 HCAPLUS
CN 1,2-Pyrrolidinedicarboxamide,
N1-(4-ethynylphenyl)-4-hydroxy-N2-[3-methoxy-
4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 814264-29-4 HCAPLUS
CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-N2-[4-(3-oxo-4-
morpholinyl)phenyl]-4-(2-propenyloxy)-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 814264-30-7 HCAPLUS

L17 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 814264-25-0 HCAPLUS
CN 1,2-Pyrrolidinedicarboxamide, N2-(1-acetyl-2,3-dihydro-1H-indol-5-yl)-N1-
(4-ethynylphenyl)-4-hydroxy-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 814264-26-1 HCAPLUS
CN 1H-Indole-2-carboxylic acid, 5-[[[(2R,4R)-1-[[[(4-ethynylphenyl)amino]carbonyl]-4-hydroxy-2-pyrrolidinyl]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 814264-27-2 HCAPLUS
CN 1,2-Pyrrolidinedicarboxamide,
N1-(4-ethynylphenyl)-4-methoxy-N2-[3-methoxy-


L17 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
N1-(4-ethynylphenyl)-N2-[2-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-4-(2-propenyloxy)-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 814264-31-8 HCAPLUS
CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-N2-[4-(3-oxo-4-
morpholinyl)phenyl]-4-(2-propenyloxy)-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 814264-32-9 HCAPLUS
CN 1,2-Pyrrolidinedicarboxamide,
N1-(4-ethynylphenyl)-N2-[2-fluoro-4-(3-oxo-4-
morpholinyl)phenyl]-4-(2-propenyloxy)-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 814264-33-0 HCAPLUS

22/08/2007,10561227.trn


L17 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-N2-[2-fluoro-4-(2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 814264-34-1 HCAPLUS
CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-4-methoxy-N2-[3-methyl-4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 814264-35-2 HCAPLUS
CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-N2-[3-methyl-4-(3-oxo-4-morpholinyl)phenyl]-4-(2-propynyloxy)-, (2R,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 814264-36-3 HCAPLUS
CN 1,2-Pyrrolidinedicarboxamide, 4-(2,3-dihydroxypropoxy)-N1-(4-ethynylphenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 814264-37-4 HCAPLUS
CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-4-methoxy-N2-[4-(5-methyl-2-oxo-1(2H)-pyridinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L17 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 814264-38-5 HCAPLUS
CN L-Proline, 1-[4-[[[(2R,4R)-1-[[[(4-ethynylphenyl)amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]phenyl]-4-hydroxy-, methyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 814264-39-6 HCAPLUS
CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-N2-[2-fluoro-4-(3-methyl-2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy-, (2S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 814264-40-9 HCAPLUS
CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-N2-[2-fluoro-4-(3-methyl-2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 814264-41-0 HCAPLUS
CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-4-(2-methoxyethoxy)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 814264-42-1 HCAPLUS
CN Acetic acid, [[[(3R,5R)-1-[[[(4-ethynylphenyl)amino]carbonyl]-5-[[[(4-3-oxo-4-morpholinyl)phenyl]amino]carbonyl]-3-pyrrolidinyl]oxy]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




22/08/2007,10561227.trn

L17 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 814264-43-2 HCAPLUS
CN Acetic acid,
[[[(2R,5R)-1-[[[(4-ethynylphenyl)amino]carbonyl]-5-[[[4-(3-oxo-4-morpholinyl)phenyl]amino]carbonyl]-3-pyrrolidinyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 814264-44-3 HCAPLUS
CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-4-methoxy-N2-[4-(3-methyl-6-oxo-1(6H)-pyridazinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 814264-45-4 HCAPLUS
CN 1,2-Pyrrolidinedicarboxamide,
N1-(4-ethynylphenyl)-4-(2-methoxyethoxy)-N2-[2-methyl-4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L17 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 814264-46-5
RL: RCT (Reactant), RACT (Reactant or reagent)
(preparation of pyrrolidinyldicarboxylic acids and related compds. as factor Xa and factor VIIa inhibitors)

RN 814264-46-5 HCAPLUS
CN 1,2-Pyrrolidinedicarboxamide,
N1-(4-ethynylphenyl)-N2-[2-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-4-(2-methoxyethoxy)-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

22/08/2007,10561227.trn

=> log h

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

18.41

817.66

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-2.34

-42.90

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 13:39:47 ON 10 MAY 2007